191 related articles for article (PubMed ID: 9593132)
1. Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.
Eliopoulos GM; Wennersten CB; Gold HS; Schülin T; Souli M; Farris MG; Cerwinka S; Nadler HL; Dowzicky M; Talbot GH; Moellering RC
Antimicrob Agents Chemother; 1998 May; 42(5):1088-92. PubMed ID: 9593132
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium.
Bonilla HF; Perri MB; Kauffman CA; Zervos MJ
Diagn Microbiol Infect Dis; 1996 Jul; 25(3):127-31. PubMed ID: 8902408
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci.
Eliopoulos GM; Wennersten CB
Antimicrob Agents Chemother; 2002 May; 46(5):1319-24. PubMed ID: 11959562
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of quinupristin/dalfopristin and other antibiotics against ampicillin-resistant enterococcus faecium.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):119-23. PubMed ID: 10677922
[TBL] [Abstract][Full Text] [Related]
6. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
[TBL] [Abstract][Full Text] [Related]
7. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens.
McDonald LC; Rossiter S; Mackinson C; Wang YY; Johnson S; Sullivan M; Sokolow R; DeBess E; Gilbert L; Benson JA; Hill B; Angulo FJ
N Engl J Med; 2001 Oct; 345(16):1155-60. PubMed ID: 11642231
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
9. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
10. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.
Caron F; Gold HS; Wennersten CB; Farris MG; Moellering RC; Eliopoulos GM
Antimicrob Agents Chemother; 1997 Dec; 41(12):2749-53. PubMed ID: 9420051
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium.
Hill RL; Smith CT; Seyed-Akhavani M; Casewell MW
J Antimicrob Chemother; 1997 May; 39 Suppl A():23-8. PubMed ID: 9511058
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of mupirocin, daptomycin, linezolid, quinupristin/dalfopristin and tigecycline against vancomycin-resistant enterococci (VRE) from clinical isolates in Korea (1998 and 2005).
Lee DK; Kim Y; Park KS; Yang JW; Kim K; Ha NJ
J Biochem Mol Biol; 2007 Nov; 40(6):881-7. PubMed ID: 18047782
[TBL] [Abstract][Full Text] [Related]
13. Characteristic of Enterococcus faecium clinical isolates with quinupristin/dalfopristin resistance in China.
Wang S; Guo Y; Lv J; Qi X; Li D; Chen Z; Zhang X; Wang L; Yu F
BMC Microbiol; 2016 Oct; 16(1):246. PubMed ID: 27769188
[TBL] [Abstract][Full Text] [Related]
14. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
Lorian V; Fernandes F
Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
[TBL] [Abstract][Full Text] [Related]
15. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium.
Bozdogan B; Leclercq R
Antimicrob Agents Chemother; 1999 Nov; 43(11):2720-5. PubMed ID: 10543753
[TBL] [Abstract][Full Text] [Related]
16. Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations.
Aeschlimann JR; Zervos MJ; Rybak MJ
Antimicrob Agents Chemother; 1998 Oct; 42(10):2710-7. PubMed ID: 9756782
[TBL] [Abstract][Full Text] [Related]
17. Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.
Matsumura SO; Louie L; Louie M; Simor AE
Antimicrob Agents Chemother; 1999 Nov; 43(11):2776-9. PubMed ID: 10543762
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
[TBL] [Abstract][Full Text] [Related]
19. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibilities of clinical isolates of vancomycin-resistant enterococci in Taiwan.
Hsueh PR; Wu JJ; Lu JJ; Teng LJ; Luh KT
J Formos Med Assoc; 1999 Jan; 98(1):45-8. PubMed ID: 10063273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
